BACKGROUND Human papillomaviruses (HPVs) play an obligatory role in cervical cancer development. Thus, immunization of women using a prophylactic vaccine against the most common high-oncogenic risk types (e.g., HPV 16 and 18) and HPV 6 and 11, which contribute to development of low-grade cervical lesions and cause most anogenital warts, represents a logical primary prevention strategy. PERSPE...

Background: Human papillomavirus is the main causative agent of cervical cancer. The HPV vaccination targets young adolescent girls that need parents’ consent for medical interventions. Objectives: To determine the practice of adolescent girls HPV vaccination, their mothers’ knowledge and attitude to HPV and HPV vaccination. Methods: This cross-sectional prospective study surveyed mothers of ad...

BACKGROUND In November 2011, the GAVI Alliance made the decision to add HPV vaccine as one of the new vaccines for which countries eligible for its funding (less than $1520 per capita income) could apply to receive support for national HPV vaccination, provided they could demonstrate the ability to deliver HPV vaccines. This paper describes the data and analysis shared with GAVI policymakers fo...

Academic research described in the late 1980’s the causal association between human papillomavirus (HPV) and cervical cancer, later expanded to significant fractions of all other genital tract cancers in both genders as well as a proportion of the cancers of the oral cavity and oropharynx. Prophylactic phase III HPV vaccine trials have shown complete type specific vaccine efficacy against two H...

OBJECTIVE Evaluation of the long-term HPV-16/18 AS04-adjuvanted vaccine immunogenicity persistence in women. DESIGN Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase-III study (NCT00196937). SETTING Six centres in Germany and Poland. POPULATION 488 healthy women (aged 15-55 years, age-stratified into groups: 15-25, 26-45, and 46-55 years) who received three vac...

Ninety-one HIV-infected individuals (61 men and 30 women) were randomized to vaccination either with quadrivalent (Gardasil™) or bivalent (Cervarix™) HPV vaccine. Neutralizing and specific HPV-binding serum antibodies were measured at baseline and 12 months after the first vaccine dose. Presence of neutralizing and binding antibodies had good agreement (average Kappa for HPV types 6, 11, 16, 18...

OBJECTIVE Anal cancer and other diseases caused by human papillomavirus (HPV) are more common among people who are HIV-positive. To understand the potential role of HIV status in HPV prevention efforts, we examined HPV-related knowledge, attitudes, and beliefs among HIV-positive and HIV-negative gay men. MATERIALS AND METHODS In January 2009, we interviewed a national sample of 247 adult gay ...

WHIM-syndrome is an inherited immunodeficiency disorder with abnormal susceptibility to human papillomavirus (HPV) infection and diseases. We determined safety and immunogenicity to a quadrivalent HPV vaccine in WHIM-syndrome by detection of HPV-specific antibodies and lymphoproliferation. In virus-like-particle (VLP)-ELISA, a WHIM patient showed antibody titers up to 400 for HPV-6/11/16/18, wh...

OBJECTIVES To determine the level of knowledge of HPV related oropharyngeal cancer and practice patterns of HPV vaccine use by pediatricians. STUDY DESIGN, SUBJECTS, METHODS IRB approved 18-question survey was administered to members of the Louisiana Chapter of the American Academy of Pediatrics. RESULTS We received 116 responses (response rate: 15.9 percent );. 104 respondents (89.66 perce...

The role of HPV as the causative factor in cervical cancer has led to the development of the HPV vaccines Gardasil and Cervarix. These vaccines effectively protect against two HPV types associated with 70% of cervical cancer cases. Despite this success, researchers continue to develop second-generation HPV vaccines to protect against more HPV types and allow increased uptake in developing count...